# Prospective Evaluation of Subcutaneous Administration of Daratumumab by the FreedomEDGE® Infusion System

> **NCT07721350** · NA · NOT_YET_RECRUITING · sponsor: **Hospices Civils de Lyon** · enrollment: 100 (estimated)

## Conditions studied

- Multiple Myeloma or Amyloidosis

## Interventions

- **DEVICE:** Subcutaneous Daratumumab Administration Using FreedomEDGE®

## Key facts

- **NCT ID:** NCT07721350
- **Lead sponsor:** Hospices Civils de Lyon
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-10
- **Primary completion:** 2027-05
- **Final completion:** 2027-05
- **Target enrollment:** 100 (ESTIMATED)
- **Last updated:** 2026-07-23

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07721350

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07721350, "Prospective Evaluation of Subcutaneous Administration of Daratumumab by the FreedomEDGE® Infusion System". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07721350. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*